Story Details
| Last Updated | |
| Total Articles | 6 |
Main Topics
research involving fundamental scientific principles that may apply to a preclinical understanding – to clinical research, which involves studies of people who may be subjects in clinical trials
News on this topic
Prozess um brutale Schlägerei in Hannovers Rotlichtviertel: Türsteher zu Bewährungsstrafe verurteilt
reuters.com/business/healthcare-pharmaceuticals/astrazeneca-magic-faces-rare-test-after-trial-failure-share-slide-2026-07-24/
Similar to This
Previous
AstraZeneca and BMS: Why the biggest deal in history is surprising: The British pharmaceutical company AstraZeneca and its US competitor Bristol Myers Squibb are ...
wiwo.de/finanzen/boerse/astrazeneca-und-bms-deshalb-kommtgroesste-deal-der-geschichte-ueberraschend/100244645.html
AstraZeneca boss urges western drugmakers to move at ‘Chinese speed’: Europe and US risk being outpaced on innovation, as happened in the car industry ...
theguardian.com/business/2026/jul/27/astrazeneca-boss-urges-western-drugmakers-to-move-at-chinese-speed
STAT Jun 09
Gilead and Merck’s latest trial success and flop: Today's biotech news includes AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition ...
statnews.com/2026/06/09/biotech-news-gilead-and-merck-latest-trial-success-and-flop/
AstraZeneca CEO Pascal Soriot delivers remarks as firm celebrates transfer to NYSE
qz.com/astrazeneca-ceo-pascal-soriot-nyse-transfer
AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success
cnbc.com/2026/06/05/astrazeneca-ceo-says-ai-is-reshaping-drug-development-and-helping-boost-the-odds-of-success.html
AstraZeneca CEO: “If prices are too low, we won’t bring the drugs to market”: Pascal Soriot, CEO of the pharmaceutical company AstraZeneca, is threatening to ...
wiwo.de/unternehmen/industrie/astrazeneca-chef-sind-die-preise-zu-niedrig-bringen-wir-die-medikamente-nicht-auf-den-markt/100218667.html
Dividend guarantor AstraZeneca keeps growing – pharmaceutical giant on track: AstraZeneca exceeds expectations with Q3 growth and confirms targets for 2030.
deraktionaer.de/artikel/pharma-biotech/dividenden-garant-astrazeneca-waechst-und-waechst-pharma-riese-auf-kurs-20389877.html
AstraZeneca’s listing rejig spells long-term danger for London: It’s not skipping off entirely to New York, but pharma giant sets a worrying precedent for UK ...
theguardian.com/business/nils-pratley-on-finance/2025/sep/29/astrazenecas-listing-rejig-spells-long-term-danger-for-london
Ministers take note: now is the moment to fight to keep AstraZeneca’s listing in London
theguardian.com/business/nils-pratley-on-finance/2025/jul/29/ministers-now-is-the-moment-to-fight-to-keep-astrazeneca-london-listing
AstraZeneca pledges $50bn investment in the US amid 200% tariff fears: British-Swedish pharmaceutical company AstraZeneca is expanding its presence in the US in ...
euronews.com/business/2025/07/22/astrazeneca-pledges-50bn-investment-in-the-us-amid-200-tariff-fears
Astrazeneca chief ‘wants to shift London listing to US’: The boss of Astrazeneca has reportedly voiced his desire to transfer the pharma giant's listing to the ...
cityam.com/astrazeneca-chief-wants-to-shift-listing-to-us/
AstraZeneca boss ‘wants to shift stock market listing to US’: Report claims CEO Pascal Soriot talked in private about moving UK’s most valuable listed company ...
theguardian.com/business/2025/jul/01/astrazeneca-boss-wants-to-shift-stock-market-listing-to-us
AstraZeneca Loses Spot as UK’s Most Valuable Company to HSBC: AstraZeneca Plc lost its crown as the UK’s most valuable listed company after US President Donald ...
bloomberg.com/news/articles/2025-05-12/astrazeneca-loses-spot-as-uk-s-most-valuable-company-to-hsbc
Paid articlePaywall Drugmaker AstraZeneca shifts more production to US amid Trump tariffs: UK and rest of Europe risk losing out to US and China unless they ramp up spending on new ...
theguardian.com/business/2025/apr/29/astrazeneca-production-us-trump-tariffs-uk-europe-pascal-soriot
AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy: Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up ...
reut.rs/41NdKD2
AstraZeneca aims for $80 bln in total revenue by 2030: AstraZeneca aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday ...
reuters.com/business/healthcare-pharmaceuticals/astrazeneca-aims-deliver-80-billion-total-revenue-by-2030-2024-05-21/
Key FactsAstraZeneca Aims to Nearly Double Revenues by 2030
May 21, 2024 · Reading time: ~30 sec.
Summary created with AI assistance · Source: theguardian.com
Summary created with AI assistance · Source: theguardian.com
- Britain’s biggest drugmaker, AstraZeneca, aims to achieve $80 billion in revenues by 2030 from treatments for cancer, rare diseases, and other conditions.
- Presenting growth plans to shareholders in Cambridge, England, CEO Pascal Soriot stated that 12 of the 20 new drugs have the potential to generate over $5 billion in annual revenues, including five cancer treatments.
- AstraZeneca has revamped its drugs pipeline and developed a strong portfolio of cancer, cardiovascular, metabolic, respiratory, and rare disease medicines.
- The company announced plans to build a new factory in Singapore for manufacturing a new generation of cancer-killing drugs and is entering the weight-loss drug market with an obesity and diabetes pill licensed from China.
AstraZeneca targets 2024 growth but mixed views hit shares: AstraZeneca (AZN.L) expects to boost 2024 revenue and profit on the back of its blockbuster cancer ...
reuters.com/business/healthcare-pharmaceuticals/astrazeneca-sees-higher-annual-revenue-profit-2024-02-08/
/cloudfront-us-east-2.images.arcpublishing.com/reuters/R7JPLAI6MJIGBJRFBETHJ32CKY.jpg)
AstraZeneca succession sickness demands urgent fix: Can a CEO be worth $9 billion? That’s the question posed by the 4% fall in AstraZeneca’s (AZN ...
reuters.com/breakingviews/astrazeneca-succession-sickness-demands-urgent-fix-2023-09-15/
/cloudfront-us-east-2.images.arcpublishing.com/reuters/R4BFFXOPUNP4LNHL32FZDEVTJQ.jpg)
Next